Clinical trial
Track and Treat in NSCLC (TATIN) - ctDNA Guided Treatment of Early Resistance to Targeted Treatment in Patients With EGFR Positive NSCLC
NCT04148066 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Track and Treat in NSCLC (TATIN) - ctDNA Guided Treatment of Early Resistance to Targeted Treatment in Patients With EGFR Positive NSCLC
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 17, 2019
- Completion date
- December 17, 2021
- Enrollment
- 104 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.